PAG
LCTX icon

Private Advisor Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Private Advisor Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,029
Closed -$31.6K – 2724
2026
Q1 		$31.6K Sell
20,029
-29
-0.1% -$49 ﹤0.01% 2604
2025
Q4 		$33.5K Hold
20,058
– – ﹤0.01% 2541
2025
Q3 		$33.9K Hold
20,058
– – ﹤0.01% 2474
2025
Q2 		$18.2K Hold
20,058
– – ﹤0.01% 2400
2025
Q1 		$9.06K Buy
+20,058
New +$11.8K ﹤0.01% 2287
2020
Q3 		– Sell
-66
Closed – – 2615
2020
Q2 		$0 Buy
+66
New +$58 ﹤0.01% 3882

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Private Advisor Group's LCTX Position: Q2 2026 in Review

Private Advisor Group sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 20,029 shares — an estimated $31.6K sold.

Private Advisor Group first reported a position in LCTX in Q2 2020 and held it in 6 quarters. The position peaked at $33.9K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Private Advisor Group reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Private Advisor Group sold 20,029 Lineage Cell Therapeutics shares in Q2 2026, an estimated $31.6K.
  • Private Advisor Group first reported a position in Lineage Cell Therapeutics in Q2 2020 and held it in 6 quarters.
  • Private Advisor Group's Lineage Cell Therapeutics position peaked at $33.9K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.